ADVERTISEMENT
ADVERTISEMENT
3D illustration of T cell attached to protein
“Smarter” CAR T Cells Target Tumors with Precision
Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.
“Smarter” CAR T Cells Target Tumors with Precision
“Smarter” CAR T Cells Target Tumors with Precision

Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.

Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.

chimeric antigen receptor
Delivering Combination Immunotherapies to Solid Tumors
LabTalk Podcast - A Modern Trojan Horse: Delivering Combination Immunotherapies to Solid Tumors 
The Scientist’s Creative Services Team and IsoPlexis | Apr 26, 2021 | 1 min read
Katie McKenna discusses a combination CAR T and viral therapy that kills solid tumors.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Amanda Heidt | Mar 26, 2021 | 6 min read
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
car t cell chimeric antigen receptor b cell lymphoma cd19 kymriah yescarta
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Kerry Grens | Jul 30, 2019 | 2 min read
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.
t cell b cell lymphoma car t-cell therapy chimeric antigen receptor
A Revised CAR T for Lymphoma Has Fewer Side Effects
Kerry Grens | Apr 23, 2019 | 2 min read
An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Katarina Zimmer | Jul 6, 2018 | 4 min read
Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.
New CAR T-Cell Therapy Shows Promise in Trial for Leukemia
Katarina Zimmer | Nov 21, 2017 | 2 min read
The immunotherapy, which targets CD22 on cancer cells rather than CD19, might prove useful in patients for whom previous T-cell treatments were unsuccessful. 
Researchers Build a Cancer Immunotherapy Without Immune Cells
Abby Olena, PhD | Nov 13, 2017 | 3 min read
A team has engineered two stem cell lines into “synthetic T cells” that destroy breast cancer cells in vitro. 
FDA Approves Second CAR T-Cell Therapy
Ashley P. Taylor | Oct 19, 2017 | 2 min read
The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 
Another CAR-T IPO
Jef Akst | Apr 6, 2015 | 1 min read
Cellectis goes public for a whopping $228 million—nearly double the value the company filed for in February.
To Each His Own
Mary Beth Aberlin | Apr 1, 2015 | 3 min read
Cancer treatment becomes more and more personal.
ADVERTISEMENT